Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Rapid Recommendation Update
Author:
Affiliation:
1. Massachusetts General Hospital, Boston, MA
2. American Society of Clinical Oncology, Alexandria, VA
3. UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
Abstract
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.01533
Reference3 articles.
1. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update
2. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
3. Grading quality of evidence and strength of recommendations in clinical practice guidelines Part 3 of 3. The GRADE approach to developing recommendations
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer;New England Journal of Medicine;2024-09-14
2. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01;Journal of Clinical Oncology;2024-09-12
3. Best practices for achieving consensus in HER2‐low expression in breast cancer: current perspectives from practising pathologists;Histopathology;2024-07-08
4. Trastuzumab deruxtecan in breast cancer;Critical Reviews in Oncology/Hematology;2024-06
5. Specific detection of CA242 by antibody-modified chiral symmetric double “N” metasurface biosensor;Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy;2024-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3